JP2001031549A - Agent for reconstructing dermal collagen fiber bundle and cosmetic containing the same - Google Patents
Agent for reconstructing dermal collagen fiber bundle and cosmetic containing the sameInfo
- Publication number
- JP2001031549A JP2001031549A JP11199990A JP19999099A JP2001031549A JP 2001031549 A JP2001031549 A JP 2001031549A JP 11199990 A JP11199990 A JP 11199990A JP 19999099 A JP19999099 A JP 19999099A JP 2001031549 A JP2001031549 A JP 2001031549A
- Authority
- JP
- Japan
- Prior art keywords
- agent
- fiber bundle
- reconstructing
- collagen fiber
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Saccharide Compounds (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【0001】[0001]
【発明の属する技術分野】本発明は化粧料に関し、更に
詳細には、皮膚構造の乱れを是正するのに好適な化粧料
に関する。[0001] The present invention relates to a cosmetic, and more particularly, to a cosmetic suitable for correcting disorder of skin structure.
【0002】[0002]
【従来の技術】皮膚は、生体と外界とを分ける重要な器
官であり、この為、外界より多くの損傷を受けやすい。
傷害原因としては、光やラジカル発生によるによる皮膚
構成成分の損傷や重合・架橋、構成細胞の損傷と死滅、
この為、皮膚には日常的に、この様な外界からの傷害の
跡が蓄積しており、この様な現象が年をとるにつれ、肌
が美しくなくなる原因の一つであるとも言われている。
この様な経年的変化以外にもケロイド形成であるとか、
肉芽の異常形成など傷害に伴う皮膚構造の形態的変化は
少なくない。この様な、皮膚が外界より受けた傷害に起
因する、皮膚構造の形態変化を是正する手段は、外科的
手術による以外には、現在のところ全く知られていな
い。2. Description of the Related Art The skin is an important organ that separates a living body from the outside world, and is therefore more susceptible to damage than the outside world.
Causes of injury include damage or polymerization / crosslinking of skin components due to light or radical generation, damage and death of constituent cells,
For this reason, the skin is regularly accumulated with traces of such external injuries, and it is said that such phenomena are one of the causes of the skin becoming less beautiful as it gets older. .
In addition to such a secular change, it is said that keloid formation
There are not a few morphological changes in the skin structure due to injury, such as abnormal formation of granulation. At present, there is no known means for correcting a morphological change of the skin structure caused by an injury to the skin from the outside, except by a surgical operation.
【0003】一方、後記一般式(I)に表される化合物
及び/又は塩は、植物ホルモンとして知られているが、
このものが真皮のコラーゲン線維束の再構築作用を有し
ていることは、全く知られておらず、従って、この様な
成分を含む化粧料が、傷害を受けてその構造が乱れた皮
膚に作用して、皮膚構造を再生する作用を有しているこ
とも全く知られていなかった。On the other hand, compounds and / or salts represented by the following general formula (I) are known as plant hormones,
It is not known at all that it has a restructuring effect on the collagen fiber bundle of the dermis, and therefore, cosmetics containing such components can be applied to damaged skin whose structure has been disordered. It has not been known at all that it acts to regenerate the skin structure.
【0004】[0004]
【発明が解決しようとする課題】本発明は、この様な状
況下為されたものであり、傷害を受けてその構造が乱れ
た皮膚に作用して、皮膚構造を再生する作用を有する化
粧料を提供することを課題とする。SUMMARY OF THE INVENTION The present invention has been made under such circumstances, and has a function of regenerating a skin structure by acting on skin whose structure has been disordered due to injury. The task is to provide
【0005】[0005]
【課題の解決手段】この様な状況に鑑みて、本発明者ら
は、前記皮膚構造を再生する作用を有する化粧料を有す
る化粧料を求めて、鋭意研究努力を重ねた結果、次に示
す一般式(I)に表される化合物及び/又はその塩を含
有する化粧料がその様な作用を有していることを見いだ
し、発明を完成させるに至った。以下、本発明につい
て、実施の形態を中心に詳細に説明を加える。In view of such a situation, the present inventors have intensively researched for a cosmetic having a cosmetic having an action of regenerating the skin structure. It has been found that a cosmetic containing the compound represented by the general formula (I) and / or a salt thereof has such an effect, and has completed the invention. Hereinafter, the present invention will be described in detail focusing on embodiments.
【0006】[0006]
【化2】 一般式(I) (但し、式中R1は、酸素原子を置換基内に含有しても
良い炭素数4〜16の不飽和結合を含む炭化水素基を表
し、R2は、R3に結合基団を有さない場合に於いて、
水素原子、糖残基又は炭素数1〜4のアルキル基を表
し、R3は、R2に結合基団を有さない場合に於いて、
水素原子、アシル化されていても良い糖残基又は炭素数
1〜4のアルキル基を表し、点線の結合は1個の二重結
合と1個の単結合の組合せをあらわす。)Embedded image General formula (I) (wherein, R1 represents a hydrocarbon group containing an unsaturated bond having 4 to 16 carbon atoms which may contain an oxygen atom in the substituent, and R2 represents a bonding group represented by R3. If you do not have
R3 represents a hydrogen atom, a sugar residue or an alkyl group having 1 to 4 carbon atoms, and R3 has no bonding group in R2;
Represents a hydrogen atom, a sugar residue which may be acylated, or an alkyl group having 1 to 4 carbon atoms, and a bond shown by a dotted line represents a combination of one double bond and one single bond. )
【0007】[0007]
【発明の実施の形態】(1)本発明の真皮のコラーゲン
線維束構造の再構築剤 本発明の真皮のコラーゲン線維束構造の再構築剤は、上
記一般式(I)に表される化合物及び/又はその生理的
に許容される塩からなる。ここで、式中R1は、酸素原
子を置換基内に含有しても良い炭素数4〜16の不飽和
結合を含む炭化水素基を表すが、酸素原子の含有の形態
としては、水酸基、アシロキシ基、カルボキシル基、エ
ーテル基(アルキルオキシ基)等が好ましく例示でき
る。又、炭化水素基は脂肪族でも芳香族基でも使用で
き、例えば、脂肪族基であればヒドロキシペンテニル
基、ヒドロキシヘキセニル基、メトキシペンテニル基、
エトキシペンテニル基、ノルマルブチルオキシペンテニ
ル基、フェノキシペンテニル基、フルフリル基等が好ま
しく例示できる。又、R2或いはR3に表される基は何
れか一方しか存在しない。これは、アデニン類がタート
マーを形成するため、7位に入る場合と9位に入る場合
が知られており、水素原子或いは置換基はこのどちらか
にしか入らないからである。このR2乃至はR3の存在
の選択によって、式中点線で表されている二重結合と単
結合の組合せは決定される。R2、R3の具体的な基の
種類としては、水素原子、アシル化されていても良い、
リボース残基、グルコース残基或いはアラビノース残基
等の糖残基、メチル基、エチル基、ノルマルプロピル
基、イソプロピル基、ノルマルブチル基、セカンダリー
ブチル基、ターシャリーブチル基等の炭素数1〜4のア
ルキル基等が好ましく例示できる。糖残基の有すること
ができるアシル基としては、炭素数1〜4のものが好ま
しく、アセチル基が特に好ましい。これらの内、好まし
いものは水素原子及び糖残基であり、中でも水素原子が
薬効上、特に好ましい。この時、これらの基はR2の位
置につくのが好ましい。具体的に好ましい化合物を例示
するならば、トランスゼアチン、シスゼアチン、トラン
スゼアチンリボサイド、シスゼアチンリボサイド、イソ
ゼアチン、カイネチン及び生理的に許容されるこれらの
塩等が例示できる。これらの内では、トランスゼアチ
ン、シスゼアチン、カイネチンが特に好ましい。これら
の化合物は植物体より抽出することもできるし、アデニ
ンなどを原料に合成することもできる。アデニンを原料
として合成する場合には、アセトニトリルなどを溶媒に
用い、ヘキサメチルジシラザンやトリメチルシリルクロ
ライドなどのシリル化剤を用いて窒素原子上の水素をト
リメチルシリル基で置換し、これに水酸基などの置換基
をアセチル基などで保護したハロゲン化炭化水素、フル
フリルクロライド等のハロゲン化物をルイス酸などを触
媒にカップリングさせ、しかる後にメタノール性アンモ
ニアなどの塩基を用いて脱保護すれば得ることができ
る。又、これらの配糖体は、これらの化合物をトリメチ
ルシリル化した後、糖のアセチル化体と酸化銀などを触
媒にカップリングさせ、脱保護すれば得ることができ
る。又、この様なアデニン誘導体はその多くのものが試
薬として市販されており、これらを用いることもでき
る。かくして得られた本発明の真皮のコラーゲン線維束
構造の再構築剤は真皮のコラーゲン線維束構造の乱れを
再構築させ、正常な構造に修復させる作用を有する。本
発明の真皮のコラーゲン線維束構造の再構築剤を化粧料
などの皮膚外用剤に含有させて投与することにより、真
皮内部のコラーゲン線維束が崩れて引き起こす皮膚形態
の変化を予防、改善或いは治療する事ができる。本発明
をこの様な皮膚外用剤に含有させて用いる場合、好まし
い含有量は、0.001〜5重量%であり、更に好まし
くは0.005〜1重量%である。BEST MODE FOR CARRYING OUT THE INVENTION (1) Agent for Reconstructing Collagen Fiber Bundle Structure of Dermis of the Present Invention The agent for reconstructing collagen fiber bundle structure of dermis of the present invention comprises a compound represented by the above general formula (I) and And / or a physiologically acceptable salt thereof. Here, in the formula, R1 represents a hydrocarbon group containing an unsaturated bond having 4 to 16 carbon atoms which may contain an oxygen atom in the substituent, and the form of the oxygen atom contained is a hydroxyl group, an acyloxy group, or the like. Groups, carboxyl groups, ether groups (alkyloxy groups) and the like are preferred. The hydrocarbon group may be an aliphatic group or an aromatic group. For example, if the group is an aliphatic group, a hydroxypentenyl group, a hydroxyhexenyl group, a methoxypentenyl group,
Preferred examples include an ethoxypentenyl group, a normal butyloxypentenyl group, a phenoxypentenyl group, and a furfuryl group. Further, only one of the groups represented by R2 or R3 exists. This is because adenines form a tartomer, and it is known that they enter the 7-position and the 9-position, and a hydrogen atom or a substituent only enters either of them. The choice of the presence of R2 or R3 determines the combination of double and single bonds represented by the dotted lines in the formula. Specific examples of the type of R2 and R3 include a hydrogen atom and an acylated group.
A sugar residue such as a ribose residue, a glucose residue or an arabinose residue, a methyl group, an ethyl group, a normal propyl group, an isopropyl group, a normal butyl group, a secondary butyl group, a tertiary butyl group and the like having 1 to 4 carbon atoms; Preferred examples include an alkyl group. As the acyl group that the sugar residue can have, one having 1 to 4 carbon atoms is preferable, and an acetyl group is particularly preferable. Among these, preferred are a hydrogen atom and a sugar residue, and among them, a hydrogen atom is particularly preferred from the viewpoint of efficacy. At this time, these groups are preferably attached at the position of R2. Specific examples of preferred compounds include transzeatin, ciszeatin, transzeatin riboside, ciszeatin riboside, isoseatin, kinetin, and physiologically acceptable salts thereof. Of these, transzeatin, ciszeatin, and kinetin are particularly preferred. These compounds can be extracted from plants or synthesized using adenine or the like as a raw material. When adenine is synthesized as a raw material, acetonitrile or the like is used as a solvent, and hydrogen on a nitrogen atom is substituted with a trimethylsilyl group using a silylating agent such as hexamethyldisilazane or trimethylsilyl chloride, and then substituted with a hydroxyl group or the like. It can be obtained by coupling a halide such as halogenated hydrocarbon or furfuryl chloride whose group is protected with an acetyl group or the like to a catalyst using a Lewis acid or the like, followed by deprotection using a base such as methanolic ammonia. . Further, these glycosides can be obtained by trimethylsilylating these compounds, coupling an acetylated form of the sugar, silver oxide or the like to a catalyst, and deprotecting. Many of such adenine derivatives are commercially available as reagents, and these can also be used. The agent for reconstructing the collagen fiber bundle structure of the dermis of the present invention thus obtained has an action of reconstructing the disorder of the collagen fiber bundle structure of the dermis and restoring it to a normal structure. Prevention, improvement or treatment of a change in skin morphology caused by collapse of the collagen fiber bundle inside the dermis by administering the reconstituting agent of the dermal collagen fiber bundle structure of the present invention in a skin external preparation such as cosmetics. You can do it. When the present invention is used by being contained in such an external preparation for skin, the content is preferably 0.001 to 5% by weight, more preferably 0.005 to 1% by weight.
【0008】[0008]
【化3】 トランスゼアチンEmbedded image Transzeatin
【0009】[0009]
【化4】 シスゼアチンEmbedded image Ciszeatin
【0010】[0010]
【化5】 トランスゼアチンリボシド (但し、式中Riboはリボース残基を表す。)Embedded image Transzeatin riboside (where Ribo represents a ribose residue)
【0011】[0011]
【化6】 シスゼアチンリボシド (但し、式中Riboはリボース残基を表す。)Embedded image Ciszeatin riboside (where Ribo represents a ribose residue)
【0012】[0012]
【化7】 イソゼアチンEmbedded image Isoseatin
【0013】[0013]
【化8】 カイネチンEmbedded image Kinetin
【0014】(2)本発明の化粧料 本発明の化粧料は、上記真皮のコラーゲン線維束構造の
再構築剤から選ばれる1種乃至は2種以上を含有し、皮
膚の形態変化を抑制及び/又は改善する事に用いられる
ことを特徴とする。ここで、本発明の化粧料が抑制及び
/又は改善する皮膚形態の変化とは、真皮のコラーゲン
線維束構造が乱れることによって生じた、皮膚上で目視
できる皮膚形態の変化を言い、この様な皮膚形態の変化
としては、例えば、光の過剰照射や照射の累積による皮
膚の弾力消失や表面の構造の荒れ、経年の刺激蓄積に起
因する皮膚の弾力消失、ケロイドなどの生成が挙げられ
る。又、しわについても、真皮のコラーゲン線維束構造
の乱れに起因するものであれば、本発明の真皮のコラー
ゲン線維束構造の再構築剤の働きによりその生成の抑制
や改善ができるため、適用することができる。本発明の
化粧料は、その剤形としては、通常この様な皮膚の手入
れに使用されているものであれば、特段の限定無く適用
することができ、例えば、化粧水、乳液、クリーム、パ
ック化粧料、エッセンス化粧料等の基礎化粧料やアンダ
ーメークアップやファンデーションなどのメークアップ
化粧料、毛髪化粧料、洗浄用化粧料などが好ましく例示
でき、これらの中では基礎化粧料に適用するのが特に好
ましい。これは、この様な化粧料の効果発現の場が、本
発明の真皮のコラーゲン線維束構造の再構築剤のこうか
発現の場と同一であり、相加的或いは相乗的効果が得ら
れるからである。(2) Cosmetic of the Present Invention The cosmetic of the present invention contains one or two or more selected from the above-mentioned agents for reconstructing the collagen fiber bundle structure of the dermis, and suppresses morphological changes of the skin. And / or used for improvement. Here, the change in skin morphology suppressed and / or improved by the cosmetic of the present invention refers to a change in skin morphology visible on the skin caused by disorder of the collagen fiber bundle structure of the dermis. Changes in skin morphology include, for example, loss of elasticity of the skin due to excessive irradiation of light or accumulation of irradiation, roughening of the surface structure, loss of elasticity of the skin due to accumulation of stimuli over time, generation of keloids, and the like. In addition, wrinkles are also applied if they are caused by disturbance of the collagen fiber bundle structure of the dermis, because the action of the restructuring agent for the collagen fiber bundle structure of the dermis of the present invention can suppress or improve the formation thereof, and therefore it is applied. be able to. The cosmetic of the present invention can be applied in any dosage form without any particular limitation as long as it is usually used for such skin care, for example, lotion, milky lotion, cream, pack Cosmetic products, basic cosmetics such as essence cosmetics and the like, makeup cosmetics such as under makeup and foundation, hair cosmetics, washing cosmetics, etc. can be preferably exemplified. Among these, it is preferable to apply the basic cosmetics. Particularly preferred. This is because the place of such an effect of the cosmetic is the same as that of the agent for reconstructing the collagen fiber bundle structure of the dermis of the present invention, and an additive or synergistic effect can be obtained. is there.
【0015】本発明の化粧料には、上記必須成分であ
る、本発明の真皮のコラーゲン線維束構造の再構築剤以
外に、通常化粧料で使用される任意の成分を含有するこ
とができる。かか、る任意成分としては、例えば、スク
ワラン、ワセリン、マイクロクリスタリンワックス等の
炭化水素類、ホホバ油、カルナウバワックス,オレイン
酸オクチルドデシル等のエステル類、オリーブ油、牛
脂、椰子油等のトリグリセライド類、ステアリン酸、オ
レイン酸、リチノレイン酸等の脂肪酸、オレイルアルコ
ール、ステアリルアルコール、オクチルドデカノール等
の高級アルコール、スルホコハク酸エステルやポリオキ
シエチレンアルキル硫酸ナトリウム等のアニオン界面活
性剤類、アルキルベタイン塩等の両性界面活性剤類、ジ
アルキルアンモニウム塩等のカチオン界面活性剤類、ソ
ルビタン脂肪酸エステル、脂肪酸モノグリセライド、こ
れらのポリオキシエチレン付加物、ポリオキシエチレン
アルキルエーテル、ポリオキシエチレン脂肪酸エステル
等の非イオン界面活性剤類、ポリエチレングリコール、
グリセリン、1,3−ブタンジオール等の多価アルコー
ル類、増粘・ゲル化剤、酸化防止剤、紫外線吸収剤、色
剤、防腐剤、粉体、各種薬効成分等を好ましく例示でき
る。これらの中で特に好ましいものは、真皮のコラーゲ
ン線維束の再構築に有用な作用や皮膚の改善に好ましい
作用や皮膚機能の補完に好ましい作用のある、ウルソー
ル酸とそのエステル類、ヒアルロン酸ナトリウム等のム
コ多糖類、ヘパリン類似物質などの多硫酸化多糖類、ト
レハロースや硫酸化トレハロースナトリウムなどのトレ
ハロース及びその誘導体、ステロイド及びその配糖体、
メタクリロイルオキシエトキシホスファチジルコリンポ
リマー等が好ましく例示できる。これらの含有量として
は0.001〜0.5重量%程度が適当である。本発明
の化粧料は、この様な成分を常法に従って処理すること
により製造することができる。本発明の化粧料は、真皮
のコラーゲン線維束構造の再構築剤の働きにより、真皮
のコラーゲン線維束の乱れに起因する皮膚形態の変化を
抑制、改善する作用を有するので、この様な形態変化の
予防用或いは改善用に用いることが好ましい。The cosmetic of the present invention may contain, in addition to the above-mentioned essential component, the agent for reconstructing the collagen fiber bundle structure of the dermis of the present invention, any component usually used in cosmetics. Examples of the optional component include hydrocarbons such as squalane, petrolatum, and microcrystalline wax, jojoba oil, carnauba wax, esters such as octyldodecyl oleate, and triglycerides such as olive oil, tallow, and coconut oil. Fatty acids such as stearic acid, oleic acid, and ritinoleic acid; higher alcohols such as oleyl alcohol, stearyl alcohol and octyl dodecanol; anionic surfactants such as sulfosuccinates and sodium polyoxyethylene alkyl sulfate; and alkyl betaine salts. Amphoteric surfactants, cationic surfactants such as dialkylammonium salts, sorbitan fatty acid esters, fatty acid monoglycerides, their polyoxyethylene adducts, polyoxyethylene alkyl ethers, polyoxyethylene Nonionic surfactants such as alkylene fatty acid esters, polyethylene glycol,
Preferred examples include polyhydric alcohols such as glycerin and 1,3-butanediol, thickening / gelling agents, antioxidants, ultraviolet absorbers, coloring agents, preservatives, powders, and various medicinal ingredients. Particularly preferred among these are ursolic acid and its esters, sodium hyaluronate, and the like, which have a useful effect for reconstructing the collagen fiber bundle of the dermis, a favorable effect for improving the skin, and a favorable effect for complementing the skin function. Mucopolysaccharides, polysulfated polysaccharides such as heparin-like substances, trehalose and its derivatives such as trehalose and sodium sulfated trehalose, steroids and their glycosides,
A methacryloyloxyethoxyphosphatidylcholine polymer can be preferably exemplified. The content of these is suitably about 0.001 to 0.5% by weight. The cosmetic of the present invention can be produced by treating such components according to a conventional method. Since the cosmetic of the present invention has a function of suppressing and improving skin morphological changes caused by disorder of dermal collagen fiber bundles by the action of a restructuring agent of dermal collagen fiber bundle structure, such morphological changes It is preferably used for prevention or improvement.
【0016】[0016]
【実施例】以下に、実施例を挙げて、本発明について更
に詳細に説明を加えるが、本発明がこれら実施例にのみ
限定を受けないことは言うまでもない。EXAMPLES Hereinafter, the present invention will be described in more detail with reference to Examples, but it goes without saying that the present invention is not limited only to these Examples.
【0017】<実施例1>ヘアレスマウス−光累積照射
モデルを用いて、本発明の真皮のコラーゲン線維束構造
の再構築剤の作用を調べた。ヘアレスマウス(Skh:
HR−1、雌性、8週齢)の背部に連日10週紫外線
(東芝SEランプ、60mJ/cm2)を照射し、光線
維束構造損傷モデルを作製した。この動物を1群3匹に
群分けし、背部に各種被験物質0.1%の濃度の50%
エタノール水溶液を溶媒とする溶液を2週間塗布した。
対照群には50%エタノール水溶液のみを塗布した。ブ
ランクには光照射もサンプル投与も行わなかった。最後
の投与の24時間後に皮膚を採取し、NaOH法に従っ
て処理し標本を作製した。これらを電子顕微鏡にて観察
し、真皮のコラーゲン線維束の構造の乱れ具合をランク
0:観察領域全域で異常なコラーゲン線維束の構造又は
線維束構造の崩壊を認める、ランク1:過半領域で線維
束の構造の崩壊又は構造異常への変移を認める、ランク
2:一部に線維束構造の崩壊又は異常を認めるが、全体
的にはほぼ正常な線維束構造を認める、ランク3:全く
正常な線維束構造の基準で判定した。この結果を表1に
出現例数として示す。又、図1にカイネチンのランク3
のものの電子顕微鏡写真を、図2に対照のランク0のも
の電子顕微鏡写真を示す。これより、本発明の真皮の線
維束構造の再構築剤はコラーゲン線維束構造の乱れを是
正する作用に優れることがわかる。Example 1 Using a hairless mouse-cumulative light irradiation model, the effect of the agent for reconstructing the collagen fiber bundle structure of the dermis of the present invention was examined. Hairless mouse (Skh:
The back of HR-1, female, 8 weeks old) was irradiated with ultraviolet rays (Toshiba SE lamp, 60 mJ / cm 2) for 10 weeks every day to prepare a model of damage to the optical fiber bundle structure. The animals were divided into groups of 3 animals each, and a 50% concentration of each test substance 0.1% was placed on the back.
A solution using an aqueous ethanol solution as a solvent was applied for 2 weeks.
Only a 50% aqueous ethanol solution was applied to the control group. Blanks were not irradiated or sampled. 24 hours after the last administration, the skin was collected and treated according to the NaOH method to prepare a specimen. These were observed with an electron microscope, and the degree of disorder of the collagen fiber bundle structure of the dermis was ranked 0: abnormal collagen fiber bundle structure or collapse of the fiber bundle structure was observed throughout the observation region. Rank 1: fibers were found in the majority region. Degradation of the structure of the bundle or transition to structural abnormality is recognized. Rank 2: Disruption or abnormality of the fiber bundle structure is partially observed, but almost normal fiber bundle structure is recognized as a whole. Rank 3: Totally normal Judgment was made based on the standard of the fiber bundle structure. The results are shown in Table 1 as the number of occurrences. FIG. 1 shows kinetin rank 3.
FIG. 2 shows an electron micrograph of Comparative Example 1, and FIG. This shows that the agent for reconstructing the fiber bundle structure of the dermis of the present invention is excellent in the effect of correcting the disorder of the collagen fiber bundle structure.
【0018】[0018]
【表1】 [Table 1]
【0019】<実施例2>ハートレー系白色種モルモッ
トを用いて、損傷ケロイドモデルを作製し、本発明の真
皮のコラーゲン線維束構造の再構築剤のこの損傷ケロイ
ドの改善作用を調べた。即ち、モルモットの背部は剃毛
し、フロイントの不完全アジュバントと水で作製したエ
マルションを1日1回8カ所に0.1mlずつ皮内注射
し、この作業を10日間行い、傷害ケロイドを作製し
た。最後の投与から14日後に、検体の1日1回1つの
ケロイドに1サンプル0.01mlを(検体は実施例1
と同じ)経皮的に、10日間投与した。これらのケロイ
ド治癒程度を対照に比べて、ランク0:対照と同程度の
ケロイド、ランク1:対照よりやや軽度のケロイド、ラ
ンク2:対照よりかなり軽度のケロイド、ランク3:ケ
ロイド形成を行わなかったブランク部位と同程度の基準
で判定した。結果を表2に出現例数として示す。これよ
り、本発明の真皮のコラーゲン線維束構造の再構築剤は
ケロイドのような線維束の乱れに起因する皮膚形態の変
化を改善する作用に優れることがわかる。Example 2 A damaged keloid model was prepared using a Hartley white guinea pig, and the effect of the agent for reconstructing the collagen fiber bundle structure of the dermis of the present invention on the damaged keloid was examined. That is, the back of the guinea pig was shaved, 0.1 ml of an emulsion prepared with incomplete Freund's adjuvant and water was injected intradermally once a day into eight places once a day, and this operation was performed for 10 days to prepare an injury keloid. . Fourteen days after the last administration, 0.01 ml of a sample was applied to one keloid once a day (the sample was prepared in Example 1).
(Same as)) transdermally for 10 days. Compared with the control, these keloid healing levels were as follows: Rank 0: comparable keloid to the control, Rank 1: slightly less keloid than the control, rank 2: considerably less keloid than the control, rank 3: no keloid formation Judgment was made based on the same standard as the blank site. The results are shown in Table 2 as the number of occurrences. This shows that the agent for reconstructing the collagen fiber bundle structure of the dermis of the present invention is excellent in the effect of improving skin morphological changes caused by disorder of the fiber bundle such as keloid.
【0020】[0020]
【表2】 [Table 2]
【0021】<実施例3〜8>下記に示す処方に従っ
て、化粧水を作製した。即ち、処方成分を80℃で加温
可溶化し、冷却して化粧水を得た。 グリセリン 5 重量部 1,3−ブタンジオール 5 重量部 香料 0.1重量部 メチルパラベン 0.1重量部 ポリオキシエチレン(60)硬化ひまし油 0.1重量部 ヒアルロン酸ナトリウム 0.1重量部 メタクリルイルオキシエトキシジョスファチジルコリン 0.1重量部 ヘパリン類似物質 0.1重量部 本発明の真皮のコラーゲン線維束構造の再構築剤* 0.1重量部 エタノール 5.3重量部 水 84 重量部 *表3に詳細を示す。<Examples 3 to 8> Lotions were prepared according to the following formulation. That is, the formulation components were heated and solubilized at 80 ° C., and cooled to obtain a lotion. Glycerin 5 parts by weight 1,3-butanediol 5 parts by weight Fragrance 0.1 part by weight Methylparaben 0.1 part by weight Polyoxyethylene (60) hydrogenated castor oil 0.1 part by weight Sodium hyaluronate 0.1 part by weight methacrylyloxyethoxy Josfatidylcholine 0.1 part by weight Heparin-like substance 0.1 part by weight Reconstructive agent for collagen fiber bundle structure of dermis of the present invention * 0.1 part by weight 5.3 parts by weight of ethanol 84 parts by weight of water * Table 3 Show details.
【0022】[0022]
【表3】 [Table 3]
【0023】<実施例9>光の過剰照射により生じた肌
の弾力消失に悩むパネラー1群10名計70名を用い
て、実施例3〜8の化粧水と実施例3の化粧水のカイネ
チンを水に置換した比較例の化粧水を1ヶ月間使用して
もらい、弾力消失の改善の有無をアンケートにより調べ
た。結果を有効率として、表4に示す。これより、本発
明の化粧料はコラーゲン線維束の構造の乱れに起因す
る、皮膚形態の変化を改善する作用を有することがわか
る。<Example 9> The lotion of Examples 3 to 8 and the kinetin of the lotion of Example 3 were used using a total of 70 panelists, each group consisting of 10 panelists suffering from the loss of skin elasticity caused by excessive light irradiation. Was replaced with water for one month, and the presence or absence of improvement in loss of elasticity was examined by a questionnaire. Table 4 shows the results as effective rates. This indicates that the cosmetic of the present invention has an action of improving the change in skin morphology caused by the disorder of the structure of the collagen fiber bundle.
【0024】[0024]
【表4】 [Table 4]
【0025】[0025]
【発明の効果】本発明によれば、傷害を受けてその構造
が乱れた皮膚に作用して、皮膚構造を再生する作用を有
する化粧料を提供することができる。According to the present invention, it is possible to provide a cosmetic having an action of regenerating the skin structure by acting on the skin whose structure has been damaged due to injury.
【図1】 カイネチン処理のランク3のもの電子顕微鏡
写真(図面代用写真)である。FIG. 1 is an electron micrograph (a substitute for a drawing) of rank 3 of kinetin treatment.
【図2】 実施例1の対照に於けるランク0の電子顕微
鏡写真(図面代用写真)である。FIG. 2 is an electron micrograph (a substitute for a drawing) of Rank 0 in the control of Example 1.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.7 識別記号 FI テーマコート゛(参考) A61K 31/70 620 A61K 31/70 620 // C07D 473/34 351 C07D 473/34 351 C07H 19/167 C07H 19/167 (72)発明者 河合 充夫 神奈川県横浜市戸塚区柏尾町560 ポーラ 戸塚研究所内 Fターム(参考) 4C057 BB02 CC03 DD01 LL31 4C083 AC102 AC122 AC432 AC482 AC792 AC851 AC852 AD201 AD202 AD312 AD332 BB60 CC01 CC04 EE12 4C086 AA01 CB07 EA11 GA02 MA04 NA14 ZA89 ZB21 ──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. 7 Identification symbol FI Theme coat ゛ (Reference) A61K 31/70 620 A61K 31/70 620 // C07D 473/34 351 C07D 473/34 351 C07H 19/167 C07H 19/167 (72) Mitsuo Kawai Inventor F-term (reference) 4C057 BB02 CC03 DD01 LL31 4C083 AC102 AC122 AC432 AC482 AC792 AC851 AC852 AD201 AD202 AD312 AD332 BB60 CC01 CC04 EE12 4C0 AA01 CB07 EA11 GA02 MA04 NA14 ZA89 ZB21
Claims (5)
デニン誘導体及び/又は生理的に許容されるその塩から
なる真皮のコラーゲン線維束構造の再構築剤。 【化1】 一般式(I) (但し、式中R1は、酸素原子を置換基内に含有しても
良い炭素数4〜16の不飽和結合を含む炭化水素基を表
し、R2は、R3に結合基団を有さない場合に於いて、
水素原子、糖残基又は炭素数1〜4のアルキル基を表
し、R3は、R2に結合基団を有さない場合に於いて、
水素原子、アシル化されていても良い糖残基又は炭素数
1〜4のアルキル基を表し、点線の結合は1個の二重結
合と1個の単結合の組合せをあらわす。)1. An agent for reconstructing a collagen fiber bundle structure of the dermis, comprising an adenine derivative represented by the following general formula (I) and / or a physiologically acceptable salt thereof: Embedded image General formula (I) (wherein, R1 represents a hydrocarbon group containing an unsaturated bond having 4 to 16 carbon atoms which may contain an oxygen atom in the substituent, and R2 represents a bonding group represented by R3. If you do not have
R3 represents a hydrogen atom, a sugar residue or an alkyl group having 1 to 4 carbon atoms, and R3 has no bonding group in R2;
Represents a hydrogen atom, a sugar residue which may be acylated, or an alkyl group having 1 to 4 carbon atoms, and a bond shown by a dotted line represents a combination of one double bond and one single bond. )
ネチン、トランスゼアチン、シスゼアチン、トランスゼ
アチンリボシド又はシスゼアチンリボシドの何れかであ
ることを特徴とする、請求項1に記載の真皮のコラーゲ
ン線維束構造の再構築剤。2. The compound represented by the general formula (I), which is any one of kinetin, transzeatin, ciszeatin, transzeatin riboside or ciszeatin riboside. 2. The agent for reconstructing collagen fiber bundle structure of the dermis according to item 1.
ン線維束構造の再構築剤を含有する、皮膚構造再生用の
化粧料。3. A cosmetic composition for regenerating a skin structure, comprising the agent for reconstructing the collagen fiber bundle structure of the dermis according to claim 1 or 2.
的に許容されるその塩から選ばれる1種乃至は2種以上
を含有する皮膚構造再生用の化粧料。4. A cosmetic for regenerating a skin structure, comprising one or more compounds selected from the compound represented by the general formula (I) and a physiologically acceptable salt thereof.
ネチン、トランスゼアチン、シスゼアチン、トランスゼ
アチンリボシド又はシスゼアチンリボシドの何れかであ
ることを特徴とする、請求項4に記載の皮膚構造再生用
の化粧料。5. The method according to claim 4, wherein the compound represented by the general formula (I) is any of kinetin, transzeatin, ciszeatin, transzeatin riboside or ciszeatin riboside. The cosmetic for regenerating a skin structure according to claim 1.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11199990A JP2001031549A (en) | 1999-07-14 | 1999-07-14 | Agent for reconstructing dermal collagen fiber bundle and cosmetic containing the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11199990A JP2001031549A (en) | 1999-07-14 | 1999-07-14 | Agent for reconstructing dermal collagen fiber bundle and cosmetic containing the same |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2001031549A true JP2001031549A (en) | 2001-02-06 |
JP2001031549A5 JP2001031549A5 (en) | 2007-04-26 |
Family
ID=16416969
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP11199990A Pending JP2001031549A (en) | 1999-07-14 | 1999-07-14 | Agent for reconstructing dermal collagen fiber bundle and cosmetic containing the same |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2001031549A (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002255781A (en) * | 2001-03-01 | 2002-09-11 | Pola Chem Ind Inc | Skin care preparation for amelioration and prophylaxis of wrinkle |
EP1378224A1 (en) * | 2001-04-13 | 2004-01-07 | Otsuka Pharmaceutical Co., Ltd. | Sugar intake promoters |
JP2005068070A (en) * | 2003-08-25 | 2005-03-17 | Noevir Co Ltd | Skin care preparation for external use |
WO2005034902A1 (en) * | 2003-10-08 | 2005-04-21 | Otsuka Pharmaceutical Co., Ltd | Composition for promoting collagen production |
KR100779819B1 (en) | 2006-01-10 | 2007-11-28 | 김재용 | The stability technology of using the technology of the liposome including kinetin which is effective for anti-wrinkle and the components of cosmetics including the liposome and the method of manufacturing the components. |
WO2008111244A1 (en) * | 2007-03-14 | 2008-09-18 | Noevir Co., Ltd. | External preparation for skin, and food |
WO2009088050A1 (en) * | 2008-01-11 | 2009-07-16 | Otsuka Pharmaceutical Co., Ltd. | Composition for external application |
WO2009067035A3 (en) * | 2007-11-25 | 2009-09-24 | Instytut Chemii Bioorganicznej Pan | Method of obtaining of 4-n-furfurylcytosine and/or its derivatives, an anti-aging composition and use of 4-n-furfurylcytosine and/or its derivatives in the manufacture of anti-aging composition |
US7794739B2 (en) | 2002-04-09 | 2010-09-14 | Otsuka Pharmaceutical Co., Ltd. | Nucleic acid based composition for cell proliferation |
KR101030359B1 (en) * | 2003-06-27 | 2011-04-20 | 주식회사 참 존 | Cosmetic compositions containing adenine for improving skin wrinkles and preventing the appearance thereof |
EP3391879A4 (en) * | 2015-12-16 | 2019-08-21 | Guerrero Gonzalez, Tayde | Pharmaceutical composition for treating skin ulcers, injuries and burns |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4839646A (en) * | 1971-09-21 | 1973-06-11 | ||
JPS57167921A (en) * | 1981-03-17 | 1982-10-16 | Human Oltoanyagtermelo | Manufacture of epithelial formation composition |
JPH07500593A (en) * | 1991-10-16 | 1995-01-19 | リチャードソン、ビックス、インコーポレーテッド | Low pH aqueous cosmetic gel containing nonionic polyacrylamide derivative |
WO1997039733A1 (en) * | 1996-04-23 | 1997-10-30 | The Procter & Gamble Company | Methods of regulating skin appearance with vitamin b3 compound |
JPH10510240A (en) * | 1991-05-16 | 1998-10-06 | セネテック・ピーエルシー | Methods and compositions for ameliorating the adverse effects of aging |
WO1999023077A1 (en) * | 1997-11-04 | 1999-05-14 | Pfizer Products Inc. | Indazole bioisostere replacement of catechol in therapeutically active compounds |
-
1999
- 1999-07-14 JP JP11199990A patent/JP2001031549A/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4839646A (en) * | 1971-09-21 | 1973-06-11 | ||
JPS57167921A (en) * | 1981-03-17 | 1982-10-16 | Human Oltoanyagtermelo | Manufacture of epithelial formation composition |
JPH10510240A (en) * | 1991-05-16 | 1998-10-06 | セネテック・ピーエルシー | Methods and compositions for ameliorating the adverse effects of aging |
JPH07500593A (en) * | 1991-10-16 | 1995-01-19 | リチャードソン、ビックス、インコーポレーテッド | Low pH aqueous cosmetic gel containing nonionic polyacrylamide derivative |
WO1997039733A1 (en) * | 1996-04-23 | 1997-10-30 | The Procter & Gamble Company | Methods of regulating skin appearance with vitamin b3 compound |
WO1999023077A1 (en) * | 1997-11-04 | 1999-05-14 | Pfizer Products Inc. | Indazole bioisostere replacement of catechol in therapeutically active compounds |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002255781A (en) * | 2001-03-01 | 2002-09-11 | Pola Chem Ind Inc | Skin care preparation for amelioration and prophylaxis of wrinkle |
EP1378224A1 (en) * | 2001-04-13 | 2004-01-07 | Otsuka Pharmaceutical Co., Ltd. | Sugar intake promoters |
EP1378224A4 (en) * | 2001-04-13 | 2004-07-07 | Otsuka Pharma Co Ltd | Sugar intake promoters |
US7820636B2 (en) | 2001-04-13 | 2010-10-26 | Otsuka Pharmaceutical Co., Ltd. | Sugar intake promoters |
US7794739B2 (en) | 2002-04-09 | 2010-09-14 | Otsuka Pharmaceutical Co., Ltd. | Nucleic acid based composition for cell proliferation |
KR101030359B1 (en) * | 2003-06-27 | 2011-04-20 | 주식회사 참 존 | Cosmetic compositions containing adenine for improving skin wrinkles and preventing the appearance thereof |
JP2005068070A (en) * | 2003-08-25 | 2005-03-17 | Noevir Co Ltd | Skin care preparation for external use |
JP4567307B2 (en) * | 2003-08-25 | 2010-10-20 | 株式会社ノエビア | Topical skin preparation |
JP4614886B2 (en) * | 2003-10-08 | 2011-01-19 | 大塚製薬株式会社 | Composition for promoting collagen production |
AU2004279248B2 (en) * | 2003-10-08 | 2011-05-12 | Otsuka Pharmaceutical Co., Ltd. | Composition for promoting collagen production |
WO2005034902A1 (en) * | 2003-10-08 | 2005-04-21 | Otsuka Pharmaceutical Co., Ltd | Composition for promoting collagen production |
US7557093B2 (en) | 2003-10-08 | 2009-07-07 | Otsuka Pharmaceutical Co., Ltd. | Composition for promoting collagen production |
JPWO2005034902A1 (en) * | 2003-10-08 | 2006-12-21 | 大塚製薬株式会社 | Composition for promoting collagen production |
KR100779819B1 (en) | 2006-01-10 | 2007-11-28 | 김재용 | The stability technology of using the technology of the liposome including kinetin which is effective for anti-wrinkle and the components of cosmetics including the liposome and the method of manufacturing the components. |
JP2008222664A (en) * | 2007-03-14 | 2008-09-25 | Noevir Co Ltd | External preparation for skin and food |
WO2008111244A1 (en) * | 2007-03-14 | 2008-09-18 | Noevir Co., Ltd. | External preparation for skin, and food |
WO2009067035A3 (en) * | 2007-11-25 | 2009-09-24 | Instytut Chemii Bioorganicznej Pan | Method of obtaining of 4-n-furfurylcytosine and/or its derivatives, an anti-aging composition and use of 4-n-furfurylcytosine and/or its derivatives in the manufacture of anti-aging composition |
US8404660B2 (en) | 2007-11-25 | 2013-03-26 | Instytut Chemii Bioorganicznej Pan | Method of obtaining of 4-N-furfurylcytosine and/or its derivatives, an anti-aging composition and use of 4-N-furfurylcytosine and/or its derivatives in the manufacture of anti-aging composition |
WO2009088050A1 (en) * | 2008-01-11 | 2009-07-16 | Otsuka Pharmaceutical Co., Ltd. | Composition for external application |
AU2009203355B2 (en) * | 2008-01-11 | 2013-06-20 | Otsuka Pharmaceutical Co., Ltd. | Composition for external application |
US9084904B2 (en) | 2008-01-11 | 2015-07-21 | Otsuka Pharmaceutical Co., Ltd. | Composition for external application |
EP3391879A4 (en) * | 2015-12-16 | 2019-08-21 | Guerrero Gonzalez, Tayde | Pharmaceutical composition for treating skin ulcers, injuries and burns |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1032363B1 (en) | Conjugated linoleic acid delivery system in cosmetic preparations | |
JP3616708B2 (en) | Skin improvement cosmetics | |
KR101453217B1 (en) | Cosmetics compositions for humectant | |
DE102004032734A1 (en) | Prebiotic substances for deodorants | |
US4892727A (en) | Cosmetic or dermopharmaceutical compositions containing a powder of sweet lupine seeds essentially free of alkaloids | |
EP1773328A1 (en) | Prebiotic intimate personal hygiene product | |
JP2001031549A (en) | Agent for reconstructing dermal collagen fiber bundle and cosmetic containing the same | |
KR102429854B1 (en) | Multi ceramide lamellar structure comprising fatty acid and neutralizing agent | |
JP5604792B2 (en) | Pharmaceutical composition for external use | |
KR20180097781A (en) | How to handle the appearance of tapered hair | |
JP2954060B2 (en) | Use of polyholosides in cleansing or makeup removal compositions and compositions containing the polyholosides | |
JP2001031549A5 (en) | ||
WO2002083087A1 (en) | Sugar intake promoters | |
JP3910094B2 (en) | Topical skin preparation | |
JP4789334B2 (en) | Skin preparation for wrinkle improvement and prevention | |
JPH115727A (en) | Skin cosmetic | |
JP2002255781A5 (en) | ||
JPH1017430A (en) | Irritation-preventing agent, and cosmetic containing the same for preventing irritation | |
EP3330280A1 (en) | Cnp cyclic peptide, and medicine, external preparation and cosmetic each containing said cyclic peptide | |
JP2000109419A (en) | Composition for moisturizing and composition for external use for skin containing the same | |
CN108883041B (en) | Personal care compositions comprising hair repair blends | |
JP2001158730A5 (en) | ||
JP2001158730A (en) | Cosmetic for improving dark skin color | |
JP4392114B2 (en) | Dermal collagen fiber bundle reconstituting agent and composition containing the same | |
JP3667601B2 (en) | Cleaning agent for pore care |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060613 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060613 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20060613 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091201 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100330 |